KR100891762B1 - Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom - Google Patents

Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom Download PDF

Info

Publication number
KR100891762B1
KR100891762B1 KR1020070000902A KR20070000902A KR100891762B1 KR 100891762 B1 KR100891762 B1 KR 100891762B1 KR 1020070000902 A KR1020070000902 A KR 1020070000902A KR 20070000902 A KR20070000902 A KR 20070000902A KR 100891762 B1 KR100891762 B1 KR 100891762B1
Authority
KR
South Korea
Prior art keywords
weight
root
blood pressure
extract
composition
Prior art date
Application number
KR1020070000902A
Other languages
Korean (ko)
Other versions
KR20080064238A (en
Inventor
김영섭
유시용
연규환
홍경식
이병회
이병호
오광석
서호원
서지희
고우석
권대영
Original Assignee
한국화학연구원
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원, 한국식품연구원 filed Critical 한국화학연구원
Priority to KR1020070000902A priority Critical patent/KR100891762B1/en
Priority to PCT/KR2008/000052 priority patent/WO2008082268A1/en
Publication of KR20080064238A publication Critical patent/KR20080064238A/en
Application granted granted Critical
Publication of KR100891762B1 publication Critical patent/KR100891762B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065Diphenyl-substituted acyclic alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 마칠린 디 (machilin D), 사우스네올 디 (saucerneol D) 및 이들의 혼합물로 구성된 군으로부터 선택된 화합물 또는 이를 포함하는 삼백초 (Saururus chinenesis) 뿌리 추출물을 유효성분으로 함유하는 혈관 이완용 조성물에 관한 것으로서, 본 발명에 따른 조성물은 혈관 평활근 이완작용을 통해 우수한 혈압 강하효과를 나타내므로, 고혈압 및 고혈압의 합병증으로 인한 각종 심혈관계 질환의 예방 및 치료를 위한 약학 조성물 또는 건강 식품 조성물로 유용하게 사용될 수 있다.The present invention relates to a composition for vascular relaxation , comprising a compound selected from the group consisting of machilin D, south Neol D, and mixtures thereof, or Saururus chinenesis root extract comprising the same as an active ingredient. As the composition according to the present invention exhibits an excellent blood pressure lowering effect through vascular smooth muscle relaxation, it can be usefully used as a pharmaceutical composition or health food composition for the prevention and treatment of various cardiovascular diseases caused by the complications of hypertension and hypertension. have.

Description

삼백초 뿌리 추출물 또는 이로부터 분리된 활성성분을 포함하는 혈관 이완용 조성물 {COMPOSITION FOR VASORELAXANT EFFECT COMPRISING A ROOT EXTRACT OF SAURURUS CHINENESIS OR ACTIVE COMPOUNDS ISOLATED THEREFROM}Vascular relaxation composition comprising root extract or active ingredient isolated from the tritical sect root extract {COMPOSITION FOR VASORELAXANT EFFECT COMPRISING A ROOT EXTRACT OF SAURURUS CHINENESIS OR ACTIVE COMPOUNDS ISOLATED THEREFROM}

도 1은 흰 쥐 (rat)로부터 적출한 흉부 대동맥 평활근을 혈관수축제인 페닐에프린 (phenylephrine)로 처리하여 수축시킨 후, 본 발명의 삼백초 뿌리 추출물을 투여하여 혈관 평활근 이완효과를 측정한 결과이고,1 is a result of measuring the vascular smooth muscle relaxation effect by administering the trichophytium root extract of the present invention after the contraction of the thoracic aortic smooth muscle extracted from white rats treated with phenylephrine, a vasoconstrictor. ,

도 2는 흰 쥐의 흉부로부터 적출한 대동맥 평활근을 페닐에프린로 처리하여 수축시킨 후 본 발명의 삼백초 뿌리 추출물로부터 분리·정제한 활성성분 (마칠린 디, 사우스네올 디)을 투여하여 혈관 평활근 이완효과를 측정한 결과이고,FIG. 2 shows the contraction of aortic smooth muscles extracted from the chest of a white rat with phenylephrine and then contracted with phenylephrine to relax vascular smooth muscle by administering the active ingredient isolated and purified from the three hundred sec root extract of the present invention. Is the result of measuring the effectiveness,

도 3 및 4는 삼백초 뿌리의 에탄올 추출물 (10, 30 및 100 mg/kg)을 선천성 고혈압쥐 (SHR)에 2주간 경구투여하여 항 고혈압 효과 및 심박동수 변화량을 측정한 결과이며,3 and 4 is a result of measuring the antihypertensive effect and heart rate change by oral administration of ethanol extract (10, 30 and 100 mg / kg) of three hundred seconds root to congenital hypertensive rats (SHR) for 2 weeks,

도 5 및 6은 삼백초 뿌리의 에탄올 추출물 (100 mg/kg)을 선천성 고혈압쥐 (SHR)에 6주간 경구투여하여 항 고혈압 효과 및 심박동수 변화량을 측정한 결과이다.5 and 6 is a result of measuring the antihypertensive effect and heart rate change by oral administration of ethanol extract (100 mg / kg) of the root of the three hundred seconds for 6 weeks to congenital hypertensive rats (SHR).

본 발명은 삼백초 뿌리 추출물, 이로부터 분리된, 마칠린 디, 사우스네올 디 또는 이의 혼합물을 유효성분으로 함유하는 혈관 이완용 조성물에 관한 것이다. The present invention relates to a composition for vascular relaxation, containing three hundred sec root extract, isolated from it, machilin di, South Neol di or mixtures thereof.

혈압이란 맥관속을 흐르는 혈류의 압력, 즉 동맥압을 말하는 것으로, 어떤 원인에 의해 수축기 혈압이 120 mmHg(최대혈압) 이상이고 확장기 혈압이 80 mmHg(최저혈압) 이상인 경우를 고혈압이라고 한다. Blood pressure refers to the pressure of blood flow through the vessels, that is, arterial pressure. For some reason, systolic blood pressure is 120 mmHg (maximum blood pressure) or more and diastolic blood pressure is 80 mmHg (lowest blood pressure) or higher.

이러한 고혈압은 기본적으로 교감신경계의 이상 활성, 세포막의 기능 이상, 신장에서의 물 및 Na 배설 장애, PGE2, PGI2, ANP 및 EDRF 등과 같은 혈압 강하제 (antihypertensive agent)의 분비 저하, 또는 카테콜아민 (catecholamine) 또는 레닌-안지오텐신 (renin-angiotensin) 등의 고혈압 조절기능의 이상 등이 원인이 된다. 즉, 신경계, 내분비계, 세포계의 이상이 말초 저항혈관의 압력증가를 가져오고 고혈압을 유발하게 된다. 또한, 고혈압은 그 자체보다는 신부전증, 동맥경화, 뇌출혈, 뇌졸중, 실명, 심부전증 및 심장마비 등과 같은 합병증으로 인해서 사망에 이르게 되는 경우가 많다.These hypertensions are basically associated with aberrant activity of the sympathetic nervous system, dysfunction of the cell membranes, impaired excretion of water and Na in the kidneys, decreased secretion of antihypertensive agents such as PGE 2 , PGI 2 , ANP and EDRF, or catecholamines. ) Or renin-angiotensin (renin-angiotensin), such as high blood pressure control function abnormalities are caused. That is, abnormalities of the nervous system, endocrine system, and cellular system lead to an increase in pressure of peripheral resistance blood vessels and cause hypertension. Hypertension is also often caused by complications such as kidney failure, arteriosclerosis, cerebral hemorrhage, stroke, blindness, heart failure and heart failure, rather than by itself.

현재까지 고혈압의 치료를 위해서 이뇨제, 베타 차단제, 칼슘통로 억제제, 안지오텐신 전환효소 억제제, 안지오텐신 수용체 길항제 등이 개발되었다. 그러나, 고혈압은 아직까지도 치료에 의한 완치보다는 고혈압을 조절하는 조절제로서 개발 되어 왔기 때문에, 고혈압 치료를 시작하는 동시에 평생 동안 약물을 복용해야 하는 문제점을 가지고 있다. 따라서, 조직특이성이나 내성에 따른 부작용을 경감시킬 수 있는 새로운 치료제의 개발이 절실히 요구되고 있다.To date, diuretics, beta blockers, calcium channel inhibitors, angiotensin converting enzyme inhibitors, and angiotensin receptor antagonists have been developed for the treatment of hypertension. However, since hypertension has been developed as a regulator for controlling hypertension, rather than curative treatment, there is a problem in that taking medication for a lifetime while starting hypertension treatment. Therefore, there is an urgent need for the development of new therapeutic agents that can alleviate side effects due to tissue specificity or resistance.

한편, 삼백초 (三白草, Saururus chinensis)는 삼백초과 (Saururaceae) 삼백초속 (Saururus)에 속하는 다년생 초본으로서 중국에서 오래 전부터 민간약으로 사용되어 온 약초이다. 중약대사전에는 삼백초가 청리습열, 소종해독 작용이 있어, 수종, 각기, 황달, 임탁 (淋濁), 대하 (帶下), 옹저종독 (癰疽腫毒)에 효과가 있다고 기재되어 있고, 그 외 당본초, 원색천연물대사전, 본초습유, 식물명실도고, 영남채약록, 광서중약지, 본초추진 및 호남약물지 등에 기재되어 있다. 또한, 민간에서는 전초 또는 뿌리, 잎이 풍독, 이뇨, 수종, 임질, 간염, 폐렴, 변독 등의 치료 목적으로 사용되어 왔다. On the other hand, three hundred seconds (Sarurus chinensis ) is a perennial herb belonging to the three hundred genus (Saururus), a herb that has long been used as a folk medicine in China. In Chinese herbal medicine dictionary, three hundred seconds have been shown to be effective in eliminating fever and small seed detoxification, and are effective for several species, each of them, jaundice, sediment, sesame seeds, sesame seeds and sedimentary toxins. It is described in the herbal, primary natural metabolism dictionary, herbal milk, botanical name, algae, Yeongnam medicinal herb, Gwangseo medicinal herb, herb promotion and Honam medicinal herb. In addition, outposts, roots and leaves have been used in the private sector for the purpose of treatment of rubella, diuresis, species, gonorrhea, hepatitis, pneumonia, and poisoning.

삼백초의 성분에 대한 연구는 그 동안 플라보노이드류 (flavonoids), 알칼로이드류 (alkaloids), 아미노산 (amino acids), 지방산류 (fatty acids), 퀴논류 (quinones) 및 정유 성분에 대한 연구가 주로 진행되어 왔으며 전초에는 메틸-노말-노닐-케톤 (methyl-n-nonyl ketone), 줄기에는 가수분해형 탄닌이 다량 함유되어 있으며, 잎에는 퀘르세틴 (quercetin), 이소퀘르시트린 (isoquercercitrin), 아비큘라린 (avicularin), 하이페린 (hyperin), 루틴 (rutin) 및 가수분해형 탄닌이 함유되어 있으며 뿌리에는 각종 아미노산, 유기산, 당류등이 함유되어 있다고 보고되어 있다. The research on the components of the three hundred seconds has been mainly conducted on the flavonoids, alkaloids, amino acids, fatty acids, quinones and essential oils. Outpost contains methyl-n-nonyl ketone, stems contain high amounts of hydrolysable tannins, leaves contain quercetin, isoquercercitrin, abiculinin It has been reported that it contains hyperin, rutin and hydrolyzed tannins, and its roots contain various amino acids, organic acids, sugars, and the like.

한편, 쇼발 (Chaubal)등은 북미대륙의 습지에 널리 분포하는 동속 식물인 미 국 삼백초 (Saururus cernuus)의 추출물로부터 세스퀴테르펜 (sesquiterpene)계 화합물이 존재하고 있음을 보고한 바 있으며, 라오 (Rao) 등은 미국 삼백초의 추출물로부터 SC-8, SC-9, 마나산틴 A (manassantin A), 마나산틴 B (manassantin B) 및 사우서네올 (saucerneol) 이라는 화합물들을 분리하여 구조를 규명하였고, 이중 마나산틴 A가 신경충추억제 효과가 있음을 확인하였다 (Tetrahedron Lett., 24(45):4947 - 4950, 1983). 국내에서는 디메틸 텔레프탈레이트와 쿠엘세틴을 분리 동정하여 약리 작용 및 항균작용에 대한 효과가 있음을 확인하였고 (곽재욱, 경희대학교 박사학위논문, 1988), 또한 최근 삼백초의 항암작용 (등록번호 10-0248942) 및 항염증활성작용 (등록번호 10-0530274)에 대한 특허가 출원된 바 있다. Meanwhile, Chabal et al. Reported that sesquiterpene-based compounds exist from extracts of the same species, Saururus cernuus , a homogenous plant widely distributed in the wetlands of North America. ), SC-8, SC-9, manassantin A, manassantin B and saucerneol were separated from the extracts of the American trichophytium, and the structure was doubled. It was confirmed that Santin A has a neurosuppression inhibitory effect ( Tetrahedron Lett. , 24 (45): 4947-4950, 1983). In Korea, dimethyl telephthalate and quercetin were isolated and identified to have pharmacological and antimicrobial effects (Kwak Jae-wook, Ph.D. Thesis, Kyung Hee University, 1988), and also recently anti-cancer activity of three hundred seconds (Registration No. 10-0248942) And anti-inflammatory activity (Registration No. 10-0530274) has been filed.

이에 본 발명자들은 삼백초 뿌리를 포함한 여러 생약재의 추출물들의 혈관 평활근 이완작용을 조사하여 본 결과, 삼백초 뿌리의 추출물이 강력한 혈관 평활근 이완작용을 나타내고 있음을 확인하였으며, 아울러 삼백초 뿌리의 추출물로부터 혈관 평활근 이완작용을 나타내는 활성물질들을 분리, 정제하여 본 발명을 완성하게 되었다.The present inventors examined the vascular smooth muscle relaxation effect of the extracts of various herbal medicines including the root of the three hundred seconds, it was confirmed that the extract of the three hundred seconds root exhibits a potent vascular smooth muscle relaxation effect, and also from the extract of the root of three hundred seconds The present invention was completed by separating and purifying the active substances.

따라서, 본 발명의 목적은 혈관 평활근의 이완을 유도하여 고혈압 및 이로부터 야기되는 각종 심혈관질환의 예방 및 치료에 유용한, 삼백초 뿌리 추출물을 유효성분으로 함유하는 혈관 이완용 약학 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a pharmaceutical composition for vascular relaxation, containing 300 sec root extract as an active ingredient, which is useful for the prevention and treatment of hypertension and various cardiovascular diseases caused by inducing relaxation of vascular smooth muscle.

또한, 본 발명의 목적은 삼백초 뿌리 추출물을 유효성분으로 하는 혈관 이완효과를 갖는 식품을 제공하는 것이다.In addition, an object of the present invention is to provide a food having a vascular relaxation effect of the three hundred seconds root extract as an active ingredient.

상기 목적을 달성하기 위하여, 본 발명은 마칠린 디, 사우스네올 디 및 이들의 혼합물로 구성된 군으로부터 선택된 화합물 또는 이를 포함하는 삼백초 뿌리 추출물을 유효성분으로 함유하는, 혈관 이완용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for vascular relaxation, containing a compound selected from the group consisting of machinine di, South Neol di and mixtures thereof or three hundred seconds root extract comprising the same as an active ingredient.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명에 따른 약학 조성물은 혈관 평활근 이완작용을 통해 혈압 강하효과를 나타내는 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물을 유효성분으로 함유하는 것을 특징으로 한다.The pharmaceutical composition according to the present invention is characterized in that it contains three hundred sec root extract, Methylin Di, South Neol D, or mixtures thereof, which exhibit a blood pressure lowering effect through vascular smooth muscle relaxation, as an active ingredient.

먼저, 본 발명에 따른 삼백초 뿌리 추출물은 삼백초 뿌리 또는 이의 건조물을 용매 추출함으로써 제조할 수 있다. 구체적으로는, 음건하여 세절한 삼백초 뿌리에 삼백초 뿌리 부피의 2 내지 200배, 바람직하게는 10 내지 30배의 유기용매를 가하고, 10 내지 30℃에서 1 내지 20일간, 바람직하게는 5 내지 10일간 추출하고 여과한 후 감압 농축함으로써 삼백초 뿌리 추출물을 제조할 수 있다. 이때, 추출용매로는 에탄올, 에탄올 수용액, 메탄올, 메탄올 수용액, 뷰탄올, 다이클로로메탄, 에틸아세테이트, 헥산 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매를 사용할 수 있으며, 80 내지 100% 에탄올 또는 에탄올 수용액이 바람직하다.First, the three hundred sec root extract according to the present invention can be prepared by solvent extraction of three hundred sec root or its dried product. Specifically, 2 to 200 times, preferably 10 to 30 times the organic solvent of the volume of the 300 seconds is added to the dried and finely divided 300 seconds roots, 1 to 20 days, preferably 5 to 10 days at 10 to 30 ℃ After extracting, filtering and concentrating under reduced pressure, a three hundred sec root extract can be prepared. At this time, the extraction solvent may be a solvent selected from the group consisting of ethanol, ethanol aqueous solution, methanol, methanol aqueous solution, butanol, dichloromethane, ethyl acetate, hexane and mixtures thereof, 80 to 100% ethanol or ethanol aqueous solution This is preferable.

본 발명에서는, 삼백초 뿌리 추출물로부터, 혈관 이완작용을 통해 혈압 강하효과를 나타내는 특정 활성성분을 분리 및 정제하기 위하여 크로마토그래피 (chromatography)를 수행한다. 상기 크로마토그래피는 역상 또는 실리카겔 컬럼 크로마토그래피를 1 내지 2회 수행하는 것이 바람직하다. 이동상으로는 헥산/에틸아세테이트 (10: 1∼1: 1) 또는 메탄올 (50∼90%)을 사용할 수 있다. 이때, 사용하는 용매는 농도를 비극성에서 극성으로, 또는 극성에서 비극성으로 순차적으로 올려주는 농도구배 용출방식 (gradient elution)으로 용출 분리하며, 수집된 분리물의 혈관 이완 효과를 측정하여 원하는 활성 분획을 수득할 수 있다. In the present invention, chromatography is performed to isolate and purify the specific active ingredient exhibiting blood pressure lowering effect through vascular relaxation from the 300 sec root extract. Preferably, the chromatography is performed one or two times of reverse phase or silica gel column chromatography. Hexane / ethyl acetate (10: 1 to 1: 1) or methanol (50 to 90%) can be used as the mobile phase. At this time, the solvent used is eluted with a gradient gradient elution method to raise the concentration from nonpolar to polar, or from polar to nonpolar sequentially, and to obtain the desired active fraction by measuring the vascular relaxation effect of the collected isolates. can do.

혈관 이완 효과를 나타내는 활성 분획을 다시 크로마토그래피로 정제함으로써 혈관 평활근 이완작용을 통해 우수한 혈압 강하효과를 나타내는, 하기 화학식 1의 마칠린 디 및 화학식 2의 사우스네올 디를 수득할 수 있다. 또한, 필요에 따라 마칠린 디, 및 사우스네올 디를 화학적으로 합성할 수 있다. Purification by chromatography of the active fraction exhibiting a vascular relaxation effect can be obtained machylin di of the formula (1) and South Neol di of the formula (2), which exhibits an excellent blood pressure lowering effect through vascular smooth muscle relaxation. In addition, it is possible to chemically synthesize machinine di and southneol di as necessary.

Figure 112007000861590-pat00001
Figure 112007000861590-pat00001

Figure 112007000861590-pat00002
Figure 112007000861590-pat00002

본 발명의 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물은 혈관 평활근 이완작용을 통해 우수한 혈압 강하효과를 나타내므로, 고혈압 또는 고혈압 합병증의 예방 또는 치료에 사용될 수 있다. The trichophytium root extract of the present invention, Methylin Di, South Neol D, or mixtures thereof isolated from the above exhibits excellent blood pressure lowering effect through vascular smooth muscle relaxation, and thus can be used for the prevention or treatment of hypertension or hypertension complications.

상기 "고혈압"이란, 안정 상태에서 수축기 혈압, 확장기 혈압 또는 평균 동맥압 등이 정상에 비해 지속적으로 높게 유지되는 상태를 말하며, 통상적으로 수축기 혈압이 120 mmHg 이상, 확장기 혈압이 80 mmHg 이상으로 지속적으로 유지될 때를 말한다. The "hypertension" refers to a state in which the systolic blood pressure, the diastolic blood pressure or the average arterial pressure is continuously maintained higher than normal in a stable state, and the systolic blood pressure is continuously maintained at 120 mmHg or more and the diastolic blood pressure is 80 mmHg or more. Say when it will be.

"고혈압 합병증"은 혈압이 비정상적으로 상승된 상태로 유지됨에 따라 발생하는 질병을 말하는데, 예를 들면, 이에 한정되는 것은 아니지만, 관상동맥질환, 뇌혈관질환, 말초혈관질환, 대동맥질환, 신장기능장애, 심부전증 및 시력장애가 포함된다. 상기 관상동맥질환의 예로는 협심증 및 심근경색증을 들 수 있으며, 뇌혈관질환의 예로는 중풍, 뇌출혈, 뇌경색을 들 수 있다. "Hypertensive complications" refers to diseases caused by an abnormally elevated state of blood pressure, such as, but not limited to, coronary artery disease, cerebrovascular disease, peripheral vascular disease, aortic disease, renal dysfunction , Heart failure and visual impairment. Examples of coronary artery disease include angina pectoris and myocardial infarction, and examples of cerebrovascular diseases include stroke, cerebral hemorrhage, and cerebral infarction.

나아가, 본 발명에 따른 약학 조성물은 개별적으로 또는 다른 종류의 혈압 강하제와 혼합하여 투여할 수 있다. Furthermore, the pharmaceutical compositions according to the invention can be administered individually or in combination with other types of blood pressure lowering agents.

활성성분으로서 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물을 통상적인 방법에 따라 약제학적으로 허용되는 적절한 담체 또는 부형제와 혼합하거나 희석제로 희석하여 상기한 기능을 갖는 약학 조성물을 제조할 수 있다. 적합한 담체, 부형제 및 희석제의 예로는, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말디톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 상기 약학 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다.Pharmaceuticals having the above-mentioned functions by mixing, as an active ingredient, trichophytium root extract, isolated machinine di, southneol di, or mixtures thereof with a suitable pharmaceutically acceptable carrier or excipient according to conventional methods or by dilution with a diluent. The composition can be prepared. Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose , Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like.

본 발명의 약학 조성물은 포유동물에 투여된 후 활성성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 이용하여 제형화될 수 있다. 제형은 정제, 알약, 분말, 새세이 (sachet), 엘릭서 (elixir), 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사용액, 멸균 분말 등의 형태일 수 있다. The pharmaceutical compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulation may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders and the like.

본 발명의 약학 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다. 본 발명의 약학 조성물의 통상적인 1일 투여량은 유효성분을 기준으로 할 때 삼백초 뿌리 추출물은 10 내지 100 ㎎/㎏ 체중, 바람직하게는 10 내지 30 ㎎/㎏ 체중의 범위이고, 마칠린 디, 사우스네올 디 또는 이들의 혼합물은 1 내지 30 ㎎/㎏ 체중, 바람직하게는 1 내지 10 ㎎/㎏ 체중의 범위이며, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성성분의 실제 투여량은 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하며, 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical compositions of the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular. Typical daily dosages of the pharmaceutical compositions of the present invention, based on the active ingredient, 300 seconds root extract ranges from 10 to 100 mg / kg body weight, preferably 10 to 30 mg / kg body weight, Southneol di or a mixture thereof is in the range of 1 to 30 mg / kg body weight, preferably 1 to 10 mg / kg body weight, and may be administered one or several times. However, the actual dosage of the active ingredient should be determined in light of several relevant factors such as the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore the dosage limits the scope of the invention in any aspect. It is not.

또한, 본 발명에서는, 상기 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물을 포함하는, 고혈압 및 고혈압 합병증을 예방하거나 완화시킬 수 있는 건강 증진용 식품 또는 음료 조성물을 제공한다.The present invention also provides a health promotion food or beverage composition which can prevent or alleviate hypertension and hypertension complications, including the trichophytium root extract, isolated Machinin di, South Neol di or mixtures thereof. do.

상기 효과를 나타내기 위하여 본 발명의 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물을 첨가할 수 있는 식품으로는, 예를 들면 각종 식품류, 음료수, 스넥류, 과자류, 껌류, 아이스크림류, 티백차, 인스턴트차, 과립, 향료, 비타민 복합제, 및 그 밖의 건강보조식품류 등이 있으나, 이에 한정되는 것은 아니다.In order to achieve the above effects, as the food which can be added to the extract of the three hundred seconds root of the present invention, isolated Machinin di, South Neol di or a mixture thereof, for example, various foods, beverages, snacks, confectionery, gum , Ice creams, tea bags, instant teas, granules, flavorings, vitamin complexes, and other health supplements, but are not limited thereto.

본 발명의 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물을 식품 제조시 원료 물질에 첨가하거나 조리된 식품에 적절히 혼합하여 상기한 건강 증진용 식품 또는 음료를 제조할 수 있으며, 이 경우 최종적으로 제조된 식품 또는 음료 중에 삼백초 뿌리 추출물, 이로부터 분리된 마칠린 디, 사우스네올 디 또는 이들의 혼합물의 함량은 각각 0.01 내지 30 중량% 범위일 수 있다.The trichophyt root extract of the present invention, machinine di, south neol di or mixtures thereof isolated from the above may be added to the raw materials during food preparation or properly mixed with the cooked food to prepare the above-mentioned health promoting food or beverage. In this case, the content of the three hundred seconds root extract, isolated malicin di, South Neol di or mixtures thereof in the finally prepared food or beverage may be in the range of 0.01 to 30% by weight, respectively.

본 발명의 약학 조성물, 또는 건강 증진용 식품 또는 음료는 목적하는 효과를 상승시키거나 보완하기 위해 약학적으로 허용되는 다른 생약재 또는 이의 추출 물을 추가로 포함할 수 있으며, 그러한 생약재의 대표적인 예로는 목단피, 대황, 귀전우 및 연자육 등을 들 수 있다. 상기 생약재는 조성물의 총 중량을 기준으로 0.01 내지 50 중량%의 양으로 사용될 수 있다.The pharmaceutical composition, or the health promoting food or beverage of the present invention may further include other medicinal herbs or extracts thereof that are pharmaceutically acceptable to enhance or supplement the desired effect, and representative examples of such herbal medicines include , Rhubarb, citron, and lotus root. The herbal medicine may be used in an amount of 0.01 to 50% by weight based on the total weight of the composition.

이하, 본 발명을 하기 실시예에 의거하여 더욱 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 한정하지는 않는다. Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are not intended to limit the invention only.

<실시예 1> 삼백초 추출물의 제조 및 활성성분의 분리<Example 1> Preparation of three hundred vine extract and separation of active ingredient

건조된 삼백초 뿌리 1 kg을 에탄올 5 L로 일주일간 냉침시킨 후 여과하고 여액을 감압 농축하여 에탄올 추출물 127 g을 얻었다. 1 kg of dried Triticale roots were chilled with 5 L of ethanol for 1 week, filtered, and the filtrate was concentrated under reduced pressure to obtain 127 g of ethanol extract.

이 에탄올 (EtOH) 추출물 중 16g을 헥산/에틸아세테이트 혼합용액을 이동상으로서 3 ml/분의 유속으로 흘려주면서 헥산/에틸아세테이트의 혼합비를 10: 1에서부터 1: 1까지 순차적으로 올려주는 농도구배 용출방식의 실리카겔 컬럼 크로마토그래피 (silica gel column chromatography)를 실시하여 총 6개의 분획 (제1 분획 내지 제6 분획)으로 나누었다. 이 중 제5분획을 다시 역상 크로마토그래피(60∼90% 메탄올)로 정제하여, 제5-2 분획으로부터 36 mg의 마칠린 디를 분리하고, 제5-3 분획에 대해 다시 역상 크로마토그래피 (70∼90% 메탄올)를 실시하여 7 mg의 사우스네올 디를 분리하였다.Concentration elution method to raise the mixing ratio of hexane / ethyl acetate sequentially from 10: 1 to 1: 1 while flowing 16 g of the ethanol (EtOH) extract with a hexane / ethyl acetate mixed solution as a mobile phase at a flow rate of 3 ml / min. Silica gel column chromatography was performed and divided into a total of six fractions (first to sixth fractions). The fifth fraction was purified again by reversed phase chromatography (60-90% methanol) to separate 36 mg of malineline di from the 5-2 fraction, and again reversed phase chromatography (70-3). ˜90% methanol) to separate 7 mg of South Neol Di.

마칠린 디 (무색 오일) Machilin Di (Colorless Oil)

MS m/z : 344[M]+; 1H-NMR (CDCl3, 300 MHz) : δ 1.13 (3H, d, J=5.7 Hz, H-9), 1.83 (3H, dd, J=6.5, 1.2 Hz, H-9'), 3.81 (3H, s, OCH3), 3.84 (3H, s, OCH3), 4.02 (1H, m, H-8), 4.53 (1H, d, J= 8.4 Hz, H-7), 6.10 (1H, dt, J= 15.6, 6.5 Hz, H-8'), 6.31 (1H, m, H-7'), 6.76-6.87 (6H, m, Ar-H)MS m / z : 344 [M] + ; 1 H-NMR (CDCl 3, 300 MHz): δ 1.13 (3H, d, J = 5.7 Hz, H-9), 1.83 (3H, dd, J = 6.5, 1.2 Hz, H-9 '), 3.81 ( 3H, s, OCH 3 ), 3.84 (3H, s, OCH 3 ), 4.02 (1H, m, H-8), 4.53 (1H, d, J = 8.4 Hz, H-7), 6.10 (1H, dt , J = 15.6, 6.5 Hz, H-8 '), 6.31 (1H, m, H-7'), 6.76-6.87 (6H, m, Ar-H)

13C-NMR (CDCl3, 500 MHz) : δ 150.8 (C-4'), 146.9 (C-3'), 146.6 (C-3), 145.7 (C-4), 132.1 (C-1), 130.6 (C-1',7'), 125.1 (C-8'), 120.9 (C-6), 119.1 (C-6'), 118.9 (C-5'), 114.3 (C-5), 109.6 (C-2'), 109.4 (C-2), 84.3 (C-7), 78.6 (C-8), 56.0 (-OCH3), 18.6 (C-9'), 17.2 (C-9) 13 C-NMR (CDCl 3, 500 MHz): δ 150.8 (C-4 '), 146.9 (C-3'), 146.6 (C-3), 145.7 (C-4), 132.1 (C-1), 130.6 (C-1 ', 7'), 125.1 (C-8 '), 120.9 (C-6), 119.1 (C-6'), 118.9 (C-5 '), 114.3 (C-5), 109.6 (C-2 '), 109.4 (C-2), 84.3 (C-7), 78.6 (C-8), 56.0 (-OCH 3 ), 18.6 (C-9'), 17.2 (C-9)

사우스네올 디 (무색 분말) South Neol Di (Colorless Powder)

HRFABMS m/z : 554.2751 (C31H36O8NH4, calc. 554.2754); 1H-NMR (CDCl3, 300 MHz) : δ 0.70 (6H, d, J=5.7 Hz, H-9, 9'), 1.17 (3H, d, J=6.3 Hz, H-9''), 2.27 (2H, m, H-8, 8'), 3.88 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3), 4.13 (1H, m, H-8''), 4.63 (1H, d, J=8.4 Hz, H-7''), 5.42 (1H, J=6.3 Hz, H-7), 5.44 (1H, J=6.0 Hz, H-7'), 5.95 (2H, -OCH2O-), 6.76-6.99 (9H, m, Ar-H)HRFABMS m / z : 554.2751 (C 31 H 36 O 8 NH 4 , calc. 554.2754); 1 H-NMR (CDCl 3, 300 MHz): δ 0.70 (6H, d, J = 5.7 Hz, H-9, 9 '), 1.17 (3H, d, J = 6.3 Hz, H-9''), 2.27 (2H, m, H-8, 8 '), 3.88 (3H, s, OCH 3 ) , 3.89 (3H, s, OCH 3 ), 3.93 (3H, s, OCH 3 ), 4.13 (1H, m, H-8``), 4.63 (1H, d, J = 8.4 Hz, H-7``), 5.42 (1H, J = 6.3 Hz, H-7), 5.44 (1H, J = 6.0 Hz, H- 7 '), 5.95 (2H, -OCH 2 O-), 6.76-6.99 (9H, m, Ar-H)

13C-NMR (CDCl3, 500 MHz) : δ 150.7 (C-3'), 149.2 (C-3''), 149.0 (C-4''), 147.7 (C-3), 146.6 (C-4), 146.5 (C-4'), 136.8 (C-1'), 135.5 (C-1), 132.7 (C-1''), 120.2 (C-6''), 119.5 (C-6), 118.9 (C-5'), 118.8 (C-6'), 110.9 (C-5''), 110.3 (C-2'), 110.2 (C-2''), 108.0 (C-5), 107.1 (C-2), 101.1 (-OCH2O-), 84.3 (C-8''), 83.9 (C-7), 83.7 (C-7'), 78.6 (C-7''), 56.0 (-OCH3), 44.1 (C-8'), 44.0 (C-8), 17.2 (C-9''), 14.9 (C-9, 9') 13 C-NMR (CDCl 3, 500 MHz): δ 150.7 (C-3 '), 149.2 (C-3``), 149.0 (C-4''), 147.7 (C-3), 146.6 (C- 4), 146.5 (C-4 '), 136.8 (C-1'), 135.5 (C-1), 132.7 (C-1``), 120.2 (C-6 ''), 119.5 (C-6) , 118.9 (C-5 '), 118.8 (C-6'), 110.9 (C-5 ''), 110.3 (C-2 '), 110.2 (C-2''), 108.0 (C-5), 107.1 (C-2), 101.1 (-OCH 2 O-), 84.3 (C-8``), 83.9 (C-7), 83.7 (C-7 '), 78.6 (C-7''), 56.0 (-OCH 3 ), 44.1 (C-8 '), 44.0 (C-8), 17.2 (C-9``), 14.9 (C-9, 9')

한편, 에탄올 대신 물 및 헥산을 추출용매로 사용하여 뿌리의 에탄올 추출물의 제조방법과 동일한 방법으로 삼백초 뿌리의 물 추출물 및 헥산 추출물을 각각 제조하였으며, 삼백초의 뿌리 대신 잎을 사용하여 상기와 동일한 방법으로 잎의 에탄올, 물 및 헥산 추출물을 각각 제조하였다.On the other hand, water and hexane was used instead of ethanol as an extraction solvent, and water extracts and hexane extracts of the root of 300 seconds were prepared in the same manner as the method of preparing the ethanol extract of the root, respectively. Ethanol, water and hexane extracts of the leaves were prepared, respectively.

<실시예 2> 삼백초 추출물 및 이로부터 분리된 활성성분들의 혈관 이완효과 측정Example 2 Determination of Vascular Relaxation Effect of Three hundred Second Extract and Active Ingredients Isolated from the Extract

상기 실시예 1에서 얻은 삼백초의 추출물 및 마칠린 디, 사우스네올 디 각각의 적출혈관 이완효과 (즉, 혈압 강하효과로서 혈관수축제에 대한 방어효과)를 다음과 같이 측정하였다.The extract of three hundred seconds obtained in Example 1, and the extraction of vasculature-releasing effects (ie, the protective effect against vasoconstrictive agents as a blood pressure lowering effect) of each of the extracts of malinelin and south neool, were measured as follows.

스프라그-다우리 (SD, 웅성)계 흰쥐 (오리엔트 (Orient)사, 한국)를 항온(22.5±1℃), 항습 (55±5%) 및 12시간 간격으로 명암이 자동 조절되는 청정 동물 사육실에서 최소한 2주 이상 안정화시킨 후 실험에 사용하였다. SD계 흰쥐의 후두부를 강타하여 기절시킨 후 경동맥을 잘라 혈액을 유실시켰다. 흉곽을 절개한 후 하행성 대동맥을 신속하게 적출하고 내피가 손상되지 않도록 조심스럽게 지방조직 및 주위조직을 제거하였다. 이로부터 혈관을 2 내지 3 mm 길이로 잘라 크렙스-한셀레이트 완충용액 (Krebs-Henseleit 또는 Krebs' bicarbonate buffer: NaCl 118.0 mM, KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, NaHCO3 25.0 mM 및 글루코스 11.0 mM, 준세 (Junsei)사, 일본, 이하 "K-H 완충용액"이라 함)이 담긴 조직 챔버 (tissue chamber) 내에 현수하였다. 이때, 챔버 내의 온도는 37℃를 유지하였으며, O2/CO2 혼합 기체(O2: CO2=95: 5)로 포화시켜 pH를 7.4로 유지하였다. 2 g의 초기장력으로 90분 동안 평형화시켰으며, 15분 간격으로 신선한 K-H 완충용액으로 교환하였다. 혈관의 수축/이완성은 힘 변위 변환기 (force displacement transducer, 제품명: 그라스 (Grass) FT03, 그라스 (Grass)사, 미국)를 통해 차트 기록기 (chart recorder, 제품명: 멀티코더 (Multicorder) MC 6625, 휴고 사취 (Hugo Sachs)사, 독일)로 기록하였다. Sprague-Dawley (SD, male) rats (Orient, Korea) are clean animal breeding rooms with automatic adjustment of contrast at constant temperature (22.5 ± 1 ℃), humidity (55 ± 5%), and 12 hour intervals. After stabilizing at least for 2 weeks at was used in the experiment. After striking and stunning the back of the SD rat, the carotid artery was cut and blood was lost. After the incision of the rib cage, the descending aorta was quickly removed and the adipose tissue and surrounding tissue were carefully removed so as not to damage the endothelium. From this, the blood vessels were cut into 2-3 mm lengths (Krebs-Henseleit or Krebs' bicarbonate buffer: NaCl 118.0 mM, KCl 4.7 mM, CaCl 2 2.5 mM, MgSO 4 1.2 mM, KH 2 PO 4 1.2 It was suspended in a tissue chamber containing 25.0 mM of NaHCO 3 and 11.0 mM of glucose, Junsei, Japan, hereinafter referred to as "KH buffer". At this time, the temperature in the chamber was maintained at 37 ℃, saturated with O 2 / CO 2 mixed gas (O 2 : CO 2 = 95: 5) to maintain a pH of 7.4. Equilibration was carried out for 90 minutes at 2 g of initial tension and exchanged with fresh KH buffer at 15 minute intervals. Vasoconstriction / relaxation can be achieved by using a force displacement transducer (Grass FT03, Grass, USA) with a chart recorder (Multicorder MC 6625), Hugo Swine. (Hugo Sachs), Germany).

적출혈관을 조직 챔버 내에서 적응시키기 위하여, 0.3 μM의 페닐에프린(phenylephrine, 시그마-알드리치사 (Sigma-Aldrich Co.), 미국)으로 수축시킨 후, K-H 완충용액으로 45분에 걸쳐 3회 세척하였다. 상기 적출혈관을 다시 페닐에프린으로 수축시켜 안정 상태에 도달한 후, 1 μM 아세틸콜린 클로라이드 (acetylcholine chloride, 시그마 알드리치사, 미국)를 가해 혈관이 완전히 이완되는 것으로 혈관내피가 손상되지 않았음을 확인하였다. 본 실험에 사용된 검체시료 (삼백초의 추출물 및 마칠린 디, 사우스네올 디 각각)는 디메틸설폭사이드 (DMSO) 에 용해시킨 후 K-H 완충용액으로 희석하여 사용하였으며, 최고농도에서의 DMSO 농도는 0.03%였다. 실험에 사용된 모든 약물 및 시약들은 실험 개시 직전에 조제하였다.To adapt the bleeding blood vessels in the tissue chamber, it was shrunk with 0.3 μM of phenylephrine (Sigma-Aldrich Co., USA) and washed three times over 45 minutes with KH buffer. It was. After contraction of the bleeding vessel again with phenylephrine to reach a stable state, 1 μM acetylcholine chloride (acetylcholine chloride, Sigma Aldrich, USA) was added to confirm that the blood vessels were completely relaxed, indicating that the vascular endothelium was not damaged. It was. Samples used in this experiment (extract of 300 seconds, machilin di, South Neol di each) were dissolved in dimethyl sulfoxide (DMSO) and diluted with KH buffer solution, DMSO concentration at the highest concentration was 0.03% It was. All drugs and reagents used in the experiment were prepared just before the start of the experiment.

혈관 이완측정은 페닐에프린에 의해 수축된 혈관에 농도 누적법 (1, 3, 10 및 30 ㎍/㎖)으로 시료를 가해 혈관의 이완정도를 측정하였다. 이때, 실험결과는 페닐에프린에 의해 수축된 상태를 기준으로 하여 이완되는 정도를 퍼센트 (%)로 나타냈으며, 선형회귀분석을 통해 EC50 수치 (50% 이완시키는 농도)를 구하여 하기 표 1에 나타내었고, 각각의 혈관 평활근 이완효과를 그래프로서 도 1 및 2에 나타내었다.Vascular relaxation measurement was performed by adding a sample to the blood vessels contracted by phenylephrine by concentration accumulation method (1, 3, 10 and 30 µg / ml) to measure the degree of relaxation of blood vessels. At this time, the results of the experiment showed the degree of relaxation based on the contraction state by phenylephrine as a percentage (%), and obtained the EC 50 value (concentration to relax 50%) through linear regression analysis in Table 1 below. Each of the vascular smooth muscle relaxation effects is shown in FIGS. 1 and 2 as a graph.

Figure 112007000861590-pat00003
Figure 112007000861590-pat00003

도 1에서 보는 바와 같이, 삼백초 추출물 중에서 삼백초 뿌리의 에탄올 추출물, 삼백초 뿌리 헥산 추출물 및 삼백초 잎 헥산 추출물이 혈관수축제에 의해 수축된 혈관을 농도 의존적으로 이완시키며, 삼백초 뿌리의 에탄올 추출물이 가장 우수한 효과를 나타내었다. 또한, 도 2에서 보는 바와 같이 삼백초 뿌리 추출물로부터 분리·정제된 마칠린 디 및 사우스네올 디 모두가 혈관 이완작용을 유도하여 우수한 혈관 이완효과를 나타냄을 알 수 있다.As shown in Figure 1, among the three hundred extract ethanol extract of three hundred seconds root, three hundred second root hexane extract and three hundred second leaf hexane extract relaxes the blood vessels contracted by the vasoconstrictor concentration-dependent, the ethanol extract of three hundred seconds root Indicated. In addition, as shown in FIG. 2, it can be seen that both the malineline di and south neool di separated and purified from the root extract of Hundred seconds induce vascular relaxation and exhibit excellent vascular relaxation effects.

<실시예 3> 삼백초 뿌리 에탄올 추출물의 항 고혈압 효과 측정Example 3 Determination of Antihypertensive Effect of Ethanol Extract of Trituses chinensis

상기 실시예 1에서 얻은 삼백초 뿌리의 에탄올 추출물의 항고혈압 효과를 다음과 같이 측정하였다.The antihypertensive effect of the ethanol extract of the root of 300 seconds obtained in Example 1 was measured as follows.

선천성 고혈압쥐 (spontaneously hypertensive rat; SHR, 웅성, 13-14주령)는 Charles River Laboratories (미국, 1차 실험) 및 Charles River Laboratories Japan Inc. (일본, 2차 실험, confirm study)로부터 구입하였으며, 항온 (22.5±1℃), 항습 (55±5%) 및 12시간 간격으로 명암이 자동 조절되는 청정 동물 사육실에서 안정화시킨 후 실험에 사용하였다. 혈압 및 심박동수의 측정은 실험동물의 꼬리로부터 혈압을 측정하는 방법인 테일-커프법 (tail-cuff method)을 이용하여, 꼬리 광전관식 혈류 센서 (photoplethysmograph; Model 31, IITC Life Sci., Woodland Hills, CA, USA)로 측정하였다. 안정된 혈압 측정을 위하여, 실험동물을 32℃의 항온 상자에서 약 5 내지 10분간 안정화시켰으며, 실험을 개시하기 전에 1 내지 2주일간 혈압측정 훈련을 실시하였다. SHR은 수축기혈압이 170 mmHg 이상인 것만을 사용하였다.Spontaneously hypertensive rats (SHR, male, 13-14 weeks of age) were found in Charles River Laboratories (USA, primary experiment) and Charles River Laboratories Japan Inc. Purchased from Japan (Secondary experiment, confirm study) and used in experiments after stabilization in clean animal kennels with automatic adjustment of contrast at constant temperature (22.5 ± 1 ° C), humidity (55 ± 5%), and 12-hour intervals. . Blood pressure and heart rate were measured using a tail-cuff method, a method of measuring blood pressure from the tail of an experimental animal, using a photoplethysmograph (Model 31, IITC Life Sci., Woodland Hills). , CA, USA). For stable blood pressure measurement, the experimental animals were stabilized in a constant temperature box at 32 ° C. for about 5 to 10 minutes, and blood pressure measurement training was performed for 1 to 2 weeks before starting the experiment. SHR used only systolic blood pressure of 170 mmHg or more.

1차 실험에 있어서, 실험군으로는 대조군 (1% 아라비아 검 (Arabia gum)), 삼백초 뿌리의 에탄올 추출물 10, 30 및 100 mg/kg 투여군 및 대조물질인 캡토프릴(Sigma Co., 미국) 10 mg/kg 투여군 등 5군으로 나누었으며, 각 군 사이에 기준 혈압이 유의한 차이가 없도록 하여, 각 군당 8마리로 나누었다. 각 시험물질은 1% 아라비아 검을 사용하여 현탁시킨 다음 존데 (sonde)를 이용하여 경구투여 하였으며, 실험에 사용된 모든 시험물질들은 사용직전에 조제하였다. 혈압은 시험물질을 경구투여한 후 2.5 시간 후에 측정하였고, 실험시작 전일 및 시험물질 투여 후 1, 2, 3, 5, 7, 10 및 14일 후에 측정하였다.In the first experiment, the control group (1% Arabian gum), ethanol extract 10, 30 and 100 mg / kg administration group of 300 seconds root and captopril (Sigma Co., USA) as a control group The group was divided into 5 groups, such as the 10 mg / kg administration group, and divided into 8 groups in each group so that there was no significant difference in the reference blood pressure between the groups. Each test substance was suspended using 1% Arabian gum and then orally administered using sonde. All test substances used in the experiment were prepared immediately before use. Blood pressure was measured 2.5 hours after oral administration of the test substance, and the day before the start of the experiment and 1, 2, 3, 5, 7, 10 and 14 days after the test substance administration.

2차 실험은 1차 실험결과를 재확인하기 위하여 수행되었으며, 실험군으로는 대조군 (1% 아라비아 검), 삼백초 뿌리의 에탄올 추출물 (100 mg/kg) 투여군, 대조물질인 캡토프릴 (30 mg/kg) 투여군 및 SHR의 대조동물인 WKY 쥐 (Wistar-Kyoto rat; Charles River Laboratories Japan Inc.; 정상 혈압 쥐; 1% 아라비아 검) 등 4군으로 나누었으며, WKY 쥐를 제외하고는 각 군 사이에 혈압이 비슷하도록 동물을 나누었으며, WKY 군은 12마리, 그 외의 군은 각 군당 8마리로 하였다. 각 시험물질은 1% 아라비아 검을 사용하여 현탁시킨 다음 존데를 이용하여 경구투여 하였으며, 실험에 사용된 모든 시험물질들은 사용직전에 조제하였다. 혈압은 시험물질을 경구투여한 후 2.5시간 후에 측정하였고, 실험시작 전일 및 시험물질 투여 후 1, 2, 7, 14, 21, 28, 35 및 42일 후에 측정하였다. 모든 실험결과는 평균 ± 측정표준오차 (Standard Error of Measurement: SEM)로 표시하였고, 실험결과의 통계분석은 시그마 스탯 (Sigma Stat; 미국 Jandel Co.사) 프로그램을 이용하여, t-검정 (unpaired) 및 일원분산분석 (one-way analysis of variance; ANOVA)으로 처리하였고, 2차 검정은 던넷 다중 비교 검정 (Dunnett multiple comparisons test)으로 하였다.The second experiment was carried out to reconfirm the results of the first experiment. As the experimental group, the control group (1% Arabian gum), the ethanol extract (100 mg / kg) administered from the root of 300 seconds, and the control captopril (30 mg / kg) The group was divided into four groups, the WKY rat (Wistar-Kyoto rat; Charles River Laboratories Japan Inc .; normal blood pressure rat; 1% Arabian gum), the control group and the SHR control group. Animals were similarly divided into 12 groups in WKY group and 8 in each group. Each test substance was suspended using 1% Arabian gum and then orally administered using sonde. All test substances used in the experiment were prepared immediately before use. Blood pressure was measured 2.5 hours after oral administration of the test substance, and the day before the start of the experiment and 1, 2, 7, 14, 21, 28, 35 and 42 days after the test substance administration. All experimental results were expressed as mean ± Standard Error of Measurement (SEM), and statistical analysis of the experimental results was performed using the Sigma Stat (Jandel Co., USA) program, t-tested (unpaired). And one-way analysis of variance (ANOVA), and the secondary test was a Dunnett multiple comparisons test.

1차 실험결과, 시험물질인 삼백초 뿌리의 에탄올 추출물을 SHR에 경구투여한 후의 혈압변화량 (시험물질을 투여한 후의 혈압으로부터 시험물질을 투여하기 전의 혈압을 뺀 값; mmHg)을 도 3에 나타내었다. 우선, 대조군 (1% 아라비아 검), 삼백초 뿌리의 에탄올 추출물 10, 30 및 100 mg/kg 투여군 및 대조물질인 캡토프릴 10 mg/kg 투여군에서의 기준 혈압은 각각 188 ± 1.7, 187 ± 4.8, 190 ± 4.2, 190 ± 4.3 및 187 ± 3.9 mmHg으로서 각 군 사이에 유의한 차이를 보이지 않았다. 삼백초 뿌리의 에탄올 추출물 투여군은 용량 의존적으로 혈압강하를 나타냈으며, 특히 100 mg/kg 투여군에서는 투여 5일 후부터 통계학적으로 유의하게 혈압을 강하시켰는데, 이것은 대조물질인 캡토프릴 10 mg/kg을 투여했을 때와 비슷한 효과를 나타내었다. As a result of the first experiment, the change in blood pressure after oral administration of ethanol extract of the root of the test substance 300 sec to SHR (the blood pressure after administration of the test substance minus the blood pressure before administration of the test substance; mmHg) is shown in FIG. 3. . First, the reference blood pressure in the control group (1% Arabian gum), the ethanol extract 10, 30 and 100 mg / kg of the 300 seconds root and the control captopril 10 mg / kg group was 188 ± 1.7, 187 ± 4.8, 190, respectively. There was no significant difference between the groups as ± 4.2, 190 ± 4.3 and 187 ± 3.9 mmHg. The ethanol extract group in the root of 300 seconds showed blood pressure drop in dose-dependent manner, especially in the 100 mg / kg group, the blood pressure was significantly lowered after 5 days of administration, which was administered 10 mg / kg of the control compound captopril. It showed a similar effect as when done.

한편, 시험물질을 투여한 후 나타나는 심박동수 변화량 (시험물질을 투여한 후의 심박동수로부터 시험물질을 투여하기 전의 심박동수를 뺀 값; 박동수/분)을 도 4에 나타내었다. 대조군, 삼백초 뿌리의 에탄올 추출물 10, 30 및 100 mg/kg 투여군 및 대조물질인 캡토프릴 10 mg/kg 투여군에서의 기준 심박동수는 각각 391 ± 10.8, 383 ± 13.2, 407 ± 15.0, 400 ± 8.1 및 395 ± 14.4 박동수/분으로서 각 군 사이에 유의한 차이를 보이지 않았다. 삼백초 뿌리의 에탄올 추출물 10, 30 및 100 mg/kg 투여군 및 대조물질인 캡토프릴 10 mg/kg 투여군 등 모든 군이 대조군에 비해 심박동수의 변화에는 유의한 차이를 보이지 않았다.On the other hand, the amount of heart rate change after administration of the test substance (the heart rate after administration of the test substance minus the heart rate before administration of the test substance; heart rate / minute) is shown in FIG. The reference heart rates in the control group, the ethanol extract 10, 30 and 100 mg / kg administration group and the control captopril 10 mg / kg control group were 391 ± 10.8, 383 ± 13.2, 407 ± 15.0, 400 ± 8.1 and There was no significant difference between groups as 395 ± 14.4 beats / min. All groups, such as 10, 30 and 100 mg / kg ethanol extract and control group captopril 10 mg / kg, showed no significant difference in heart rate change compared to the control group.

2차 실험결과, 시험물질인 삼백초 뿌리의 에탄올 추출물을 SHR에 경구투여한 후의 혈압변화량 (시험물질을 투여한 후의 혈압으로부터 시험물질을 투여하기 전의 혈압을 뺀 값; mmHg)을 도 5에 나타내었다. 우선, 대조군 (1% Arabia gum), 삼백초 뿌리의 에탄올 추출물 100 mg/kg 투여군 및 대조물질인 캡토프릴 30 mg/kg 투여군에서의 기준 혈압은 각각 190 ± 5.7, 199 ± 4.6 및 189 ± 3.6 mmHg으로서 각 군 사이에 유의한 차이를 보이지 않았으며, SHR의 대조동물인 WKY 흰쥐의 수축기 혈압은 142 ± 3.6 mmHg으로 나타났다. 혈압은 42일 동안 1주일 간격으로 측정하였으며, 시간이 지남에 따라 WKY 흰쥐의 수축기 혈압은 조금씩 내려가는 경향을 나타냈고, SHR 대조군은 시간에 따라 혈압이 서서히 올라가는 양상을 보였다. 삼백초 뿌리의 에탄올 추출물 100 mg/kg 투여시, 투여 7일 후부터 대조군에 비해 혈압이 약 20% 가량 강하되었으며, 이것은 실험이 끝나는 42일 까지 계속되었다. 대조물질인 캡토프릴을 고용량인 30 mg/kg로 투여했을 때는 대조군에 비해 유의한 혈압강하 효과를 보였다. As a result of the second experiment, the change in blood pressure after oral administration of the ethanol extract of the root of the test substance 300 sec to SHR (the blood pressure after administration of the test substance minus the blood pressure before administration of the test substance; mmHg) is shown in FIG. 5. . First, the baseline blood pressures in the control group (1% Arabia gum), the 100 mg / kg ethanol extract of the root of 300 seconds and the control captopril 30 mg / kg, were 190 ± 5.7, 199 ± 4.6 and 189 ± 3.6 mmHg, respectively. There was no significant difference between the groups, and systolic blood pressure was 142 ± 3.6 mmHg in WKY rats. Blood pressure was measured at weekly intervals for 42 days. As time passed, systolic blood pressure of WKY rats tended to decrease gradually, and the SHR control group showed a gradually rising blood pressure. When administration of 100 mg / kg ethanol extract of the root of the 300 seconds, blood pressure dropped about 20% compared to the control group 7 days after the administration, which continued until 42 days after the end of the experiment. When control group captopril was administered at a high dose of 30 mg / kg, it showed a significant blood pressure lowering effect than the control group.

한편, 시험물질을 투여한 후 나타나는 심박동수 변화량을 도 6에 나타내었다. 대조군, 삼백초 뿌리의 에탄올 추출물 100 mg/kg 투여군 및 대조물질인 캡토프릴 10 mg/kg 투여군에서의 기준 심박동수는 각각 424 ± 10.0, 420 ± 7.9 및 406 ± 7.8 박동수/분으로서 각 군 사이에 유의한 차이를 보이지 않았다. 이때, 대조군과 비교할 때 모든 투여군에서 통계학적인 유의한 차이를 보이지는 않았지만, 캡토프릴 투여군에서는 혈압강하에 따른 반사작용으로 심박동수가 약 30 내지 40 박동수/분 정도 상승하였다.On the other hand, the heart rate change after administration of the test substance is shown in FIG. The reference heart rate in the control group, 100 mg / kg ethanol extract of the root of Trichophyte and 10 mg / kg of the control captopril was 424 ± 10.0, 420 ± 7.9 and 406 ± 7.8 beats / min, respectively. There was no difference. At this time, compared to the control group did not show a statistically significant difference in all the administration group, in the captopril administration group the heart rate increased by about 30 to 40 beats / min due to the blood pressure drop reflex action.

본 발명의 삼백초 뿌리 추출물 또는 이로부터 분리된 활성 성분을 이용하여 다음과 같이 약학 제제 또는 식품을 제조하였다.The pharmaceutical preparations or foods were prepared as follows using the trichophytium root extract of the present invention or the active ingredient isolated therefrom.

<제조예 1> 산제Production Example 1 Powder

하기 성분을 혼합한 후 통상의 산제 제조방법에 따라서 기밀포에 충진하여 산제를 제조하였다:The powders were prepared by mixing the following ingredients and then filling the airtight cloth according to a conventional powder preparation method:

삼백초 뿌리 건조 추출물 또는 이로부터 분리·정제된 활성성분 2 g3 g of root dried extract or active ingredient isolated and purified from it

유당 1 g1 g lactose

<제조예 2> 정제Preparation Example 2 Tablet

하기 성분을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조하였다:The tablets were prepared by mixing the following ingredients and then tableting according to the conventional tablet preparation method:

삼백초 뿌리 건조 추출물 또는 이로부터 분리·정제된 활성성분 100 ㎎100 grams of dried root extract or active ingredient isolated and purified from it

옥수수 전분 100 ㎎100 mg corn starch

유당 100 ㎎Lactose 100 mg

스테아린산 마그네슘 2 ㎎2 mg magnesium stearate

<제조예 3> 캡슐제Preparation Example 3 Capsule

하기 성분을 혼합한 후 통상의 캡슐제 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다:The capsules were prepared by mixing the following ingredients and filling the gelatin capsules according to a conventional capsule preparation method:

삼백초 뿌리 건조 추출물 또는 이로부터 분리·정제된 활성성분 100 ㎎100 grams of dried root extract or active ingredient isolated and purified from it

옥수수 전분 100 ㎎100 mg corn starch

유당 100 ㎎Lactose 100 mg

스테아린산 마그네슘 2 ㎎2 mg magnesium stearate

<제조예 4> 선식<Manufacture example 4> Wire type

현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 만들었다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 만들었다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to make a powder having a particle size of 60 mesh. Black beans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then ground to a powder having a particle size of 60 mesh.

본 발명의 삼백초 뿌리 추출물을 진공 농축기에서 감압 농축하고, 분무 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 삼백초 뿌리 추출물 건조 분말을 얻었다.The trichophyt root extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray hot air dryer was pulverized into a particle size of 60 mesh with a grinder to obtain a trichophytium root extract dry powder.

상기에서 제조한 곡물류, 종실류 및 삼백초 뿌리 추출물의 건조 분말을 다음의 비율로 배합하여 과립을 만들었다.Granules were prepared by combining the dry powders of the grains, seeds, and trichophytium root extracts prepared above in the following proportions.

곡물류 : 현미 30 중량%, 율무 15 중량%, 보리 20 중량%, 찹쌀 9 중량%,Cereals: Brown rice 30% by weight, barley 15% by weight, barley 20% by weight, glutinous rice 9% by weight,

종실류 : 들깨 7 중량%, 검정콩 8 중량%, 검정깨 7 중량%,Seeds: perilla 7% by weight, black beans 8% by weight, black sesame 7% by weight,

삼백초 뿌리 추출물 건조 분말 3 중량%, 영지 0.5 중량%, 지황 0.5 중량%Three hundred percent root extract dry powder 3% by weight, ganoderma lucidum 0.5% by weight, turmeric 0.5% by weight

<제조예 5> 츄잉껌Preparation Example 5 Chewing Gum

껌 베이스 20 중량%, 설탕 76.9 중량%, 향료 1 중량% 및 물 2 중량%와 본 발명의 삼백초 뿌리 추출물 0.1 중량%를 배합하여 통상의 방법으로 츄잉껌을 제조하였다.Chewing gum was prepared in a conventional manner by combining 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of perfume, and 2% by weight of water, and 0.1% by weight of Trichophyt root extract of the present invention.

<제조예 6> 캔디Production Example 6 Candy

설탕 60 중량%, 물엿 39.8 중량% 및 향료 0.1 중량%와 본 발명의 삼백초 뿌리 추출물 0.1 중량%를 배합하여 통상의 방법으로 캔디를 제조하였다.Candy was prepared in a conventional manner by combining 60% by weight of sugar, 39.8% by weight of starch syrup, and 0.1% by weight of fragrance, and 0.1% by weight of the extract of Trichophytium root.

<제조예 7> 비스켓Production Example 7 Biscuits

박력 1급 25.59 중량%, 중력 1급 22.22 중량%, 정백당 4.80 중량%, 식염 0.73 중량%, 포도당 0.78 중량%, 팜쇼트닝 11.78 중량%, 암모늄 1.54 중량%, 중조 0.17 중량%, 중아황산나트륨 0.16 중량%, 쌀가루 1.45 중량%, 비타민 B₁0.0001 중량%, 비타민 B₂0.0001 중량%, 밀크향 0.04 중량%, 물 20.6998 중량%, 전지분유 1.16 중량%, 대용분유 0.29 중량%, 제1인산칼슘 0.03 중량%, 살포염 0.29 중량% 및 분무유 7.27 중량%와 본 발명의 삼백초 뿌리 추출물 1 중량%를 배합하여 통상의 방법으로 비스켓을 제조하였다. Force 25.59% by weight, 22.22% by weight of gravity, 4.80% by weight, white salt 0.73% by weight, 0.78% by weight, palm shortening 11.78% by weight, ammonium 1.54% by weight, 0.17% by weight sodium bisulfite 0.16% by weight , Rice flour 1.45%, Vitamin B₁0.0001%, Vitamin B₂0.0001%, Milk flavor 0.04%, Water 20.6998%, Whole milk powder 1.16%, Substitute milk powder 0.29%, Monobasic calcium phosphate 0.03% , Biscuits were prepared in a conventional manner by combining 0.29% by weight of spraying salt and 7.27% by weight of spray oil with 1% by weight of the extract of Trichophyte root.

<제조예 8> 건강 음료 <Manufacture example 8> Healthy drink

꿀 0.26 중량%, 치옥토산아미드 0.0002 중량%, 니코틴산아미드 0.0004 중량%, 염산리보플라빈나트륨 0.0001 중량%, 염산피리독신 0.0001 중량%, 이노시톨 0.001 중량%, 오르트산 0.002 중량% 및 물 98.7362 중량%와 본 발명의 삼백초 뿌리 추출물 1 중량%를 배합하여 통상의 방법으로 건강 음료를 제조하였다.0.26% by weight of honey, 0.0002% by weight of thioctoamide, 0.0004% by weight of nicotinic acid, 0.0001% by weight of sodium riboflavinate, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of orthoic acid and 98.7362% by weight of water 1300% by weight of the root extract of three hundred seconds was prepared in a conventional manner for a healthy drink.

<제조예 9> 건강보조식품Preparation Example 9 Health Supplement

스피루리나 55 중량%, 구아검효소 분해물 10 중량%, 비타민 B₁염산염 0.01중량%, 비타민 B6 염산염 0.01 중량%, DL-메티오닌 0.23 중량%, 스테아린산 마그네슘 0.7 중량%, 유당 22.2 중량% 및 옥수수전분 1.85 중량%와 본 발명의 삼백초 뿌리 추출물 10 중량%를 배합하여 통상의 방법으로 정제형 건강보조식품을 제조하였다.55% by weight of spirulina, 10% by weight of guar gum enzyme digestion, 0.01% by weight of vitamin B ₁ hydrochloride, 0.01% by weight of vitamin B 6 hydrochloride, 0.23% by weight of DL-methionine, 0.7% by weight of magnesium stearate, 22.2% by weight of lactose and 1.85% by weight of corn starch % And 10% by weight of the extract of the root of the three hundred seconds of the present invention to prepare a tablet-type health supplement in a conventional manner.

상기에서 살펴본 바와 같이, 본 발명에 따른 삼백초 뿌리 추출물, 이로부터 분리·정제된 마칠린 디, 사우스네올 디를 유효성분으로 함유하는 조성물은 혈관의 평활근 이완작용을 통한 혈압 강하효과가 우수하므로, 고혈압의 예방 및 치료뿐만 아니라, 고혈압으로 야기되는 합병증, 즉 뇌졸중, 동맥경화, 허혈성 심장질환 및 울혈성 심부전 등과 같은 각종 심혈관질환의 예방 및 치료에 유용하게 사용될 수 있다.As described above, the composition containing the three hundred seconds root extract according to the present invention, isolated and purified from the Machilin di, South Neol di as an active ingredient has excellent blood pressure lowering effect through the smooth muscle relaxation of the blood vessels, hypertension In addition to the prevention and treatment of, it can be useful for the prevention and treatment of various cardiovascular diseases such as complications caused by hypertension, namely stroke, arteriosclerosis, ischemic heart disease and congestive heart failure.

Claims (7)

삭제delete 삭제delete 삭제delete 사우스네올 디 (saucerneol D) 및 이를 포함하는 삼백초 (Saururus chinenesis) 뿌리 에탄올 추출물을 함유하는, 고혈압 개선용 건강기능식품.South Neol D (saucerneol D) and a health functional food for improving hypertension containing Saururus chinenesis root ethanol extract containing the same. 제 4 항에 있어서,The method of claim 4, wherein 상기 식품이 음료의 형태인 것을 특징으로 하는 건강기능식품.Health functional food, characterized in that the food is in the form of a drink. 삭제delete 삭제delete
KR1020070000902A 2007-01-04 2007-01-04 Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom KR100891762B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020070000902A KR100891762B1 (en) 2007-01-04 2007-01-04 Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom
PCT/KR2008/000052 WO2008082268A1 (en) 2007-01-04 2008-01-04 Use of root extract of saururus chinensis for manufacture of medicament for vasorelaxation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070000902A KR100891762B1 (en) 2007-01-04 2007-01-04 Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom

Publications (2)

Publication Number Publication Date
KR20080064238A KR20080064238A (en) 2008-07-09
KR100891762B1 true KR100891762B1 (en) 2009-04-07

Family

ID=39588825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070000902A KR100891762B1 (en) 2007-01-04 2007-01-04 Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom

Country Status (2)

Country Link
KR (1) KR100891762B1 (en)
WO (1) WO2008082268A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101489478B1 (en) * 2013-06-17 2015-02-05 원광대학교산학협력단 A composition containing extract of saururi herba for the treatment of heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010036445A (en) * 1999-10-08 2001-05-07 복성해 Lignan-type compound having antioxidant activity against a low density lipoprotein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010003644A (en) * 1999-06-24 2001-01-15 윤종용 Method for detecting satate of duplicated link in atm exchange system
KR100542871B1 (en) * 2003-11-14 2006-01-20 한국생명공학연구원 Composition comprising dineolignan compounds for inhibiting acyl-CoA:cholesterol acyltransferase
KR100593793B1 (en) * 2004-04-03 2006-06-30 한국생명공학연구원 Novel lignan compound, preparation method thereof, and composition for prevention and treatment of cardiovascular disease comprising the active ingredient
KR100778031B1 (en) * 2004-10-27 2007-11-28 한국생명공학연구원 A composition comprising glycerol compounds for prevention and treatment of cardiovascular disease
KR100559495B1 (en) * 2005-10-27 2006-03-10 한국생명공학연구원 Composition comprising dineolignan compounds for inhibiting acyl-CoA:cholesterol acyltransferase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010036445A (en) * 1999-10-08 2001-05-07 복성해 Lignan-type compound having antioxidant activity against a low density lipoprotein

Also Published As

Publication number Publication date
WO2008082268A1 (en) 2008-07-10
KR20080064238A (en) 2008-07-09

Similar Documents

Publication Publication Date Title
CA2861745A1 (en) Maillard reaction inhibitor
KR102006738B1 (en) Pharmaceutical Composition comprising extracts of Justicia procumbens L. for prevention or treatment of respiratory diseases
KR100989093B1 (en) Composition Comprising the Extracts of Branch of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases
KR100732886B1 (en) Composition having antihypertensive effect comprising extract of moutan cortex radicis or active compounds isolated therefrom
KR20240023560A (en) Composition for anti-inflammation comprising extract from Tartary buckwheat
JP5064731B2 (en) Antihypertensive
KR100732888B1 (en) Composition for antihypertensive effect comprising a rhei rhizoma extract or active compounds isolated therefrom
KR100891762B1 (en) Composition for vasorelaxant effect comprising a root extract of saururus chinenesis or active compounds isolated therefrom
EP2240191A2 (en) Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases
KR101227737B1 (en) A composition comprising Ligularia stenocephala extract, fractions thereof or compounds isolated from Ligularia stenocephala extract and fractions thereof having peroxinitrite-scavenging activity
CN106715452B (en) Compound KS513, compositions containing same and uses thereof
KR100749675B1 (en) Composition for immunosuppression comprising an extract of saururus chinensis or active compounds isolated therefrom
KR100937394B1 (en) Composition for vasorelaxant effect comprising the extract of ulmus macrocarpa
KR101701124B1 (en) A composition effective in liver function with mixed extractions from moroheiya, rhubarb, coptis and Korean angelica
KR100833654B1 (en) Composition for preventing or treating osteoporosis comprising an extract of saururus chinensis or active compounds isolated therefrom
KR101403999B1 (en) A method for preparing a purified extract and the composition comprising the same for treating and preventing asthma and allergic disease
KR20080025655A (en) Composition for preventing or treating a neurodegenerative disease comprising active ingredients isolated from the stembark of vitis vinifera, which has inhibitory effect on bace-1
KR102186532B1 (en) Composition for preventing or treating a hypertensive disease comprising extract of Indigofera pseudotinctoria Matsum or fraction thereof as active ingredient
KR100704303B1 (en) Health-improving food comprising an extract of saururus chinensis or active compounds isolated therefrom
JP2014114250A (en) Xanthine oxidase inhibitor composition containing garcinia esculenta extract
KR101695166B1 (en) A composition for preventing or treating diabetic complication comprising extract of Sedum sarmentosum
KR20120116115A (en) Pharmaceutical composition for treating cancers comprising resveratrol derivatives isolated from grape stem peel
KR101944013B1 (en) Antiobesitic composition comprising extract of Quercus aliena
KR101864607B1 (en) Composition comprising pinocembrin for preventing or treating atopic dermatitis
KR20070039409A (en) Methods for increasing hmf content in asparagi tuber, and the method for extraction of hmf

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130312

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140313

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20150209

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20160323

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20170208

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee